Shanghai Fosun Pharmaceuticals Group Company Ltd (PK) (SFOSF)
USOTC
年末 2023年12月31日 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
総売上 | 14.48B | 18.31B | 24.66B | 28.33B | 30.09B | 38.78B | 43.72B | 41.13B |
営業利益 | 7.76B | 10.7B | 14.3B | 16.78B | 16.66B | 18.55B | 20.55B | 19.53B |
税引前収入 | 3.57B | 4.06B | 3.58B | 4.53B | 4.68B | 6.04B | 4.57B | 3.26B |
純利益 | 2.81B | 3.12B | 2.71B | 3.32B | 3.66B | 4.73B | 3.73B | 2.39B |
優先配当 | -845.08M | -948.15M | -820.18M | -999.53M | -1.1B | 0 | -1.44B | -721.55M |
基本的1株当たり利益 (EPS) | 0.996 | 1.049 | 0.869 | 1.066 | 1.176 | 1.518 | 1.157 | 0.74 |
EBIT | 1.85B | 2.31B | 2.49B | 1.83B | 3.12B | 1.88B | 843.94M | 746.9M |
EBITDA | 2.49B | 3.08B | 3.38B | 4.3B | 3.85B | 3.44B | 5.24B | 5.48B |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約